Preparation method of axially chiral alkenyl borate containing phosphine or carboxylic ester
Synthesis of axial chiral alkenyl borate esters under mild conditions through a copper-palladium bicatalytic system, solving the problem of the preparation of axial chiral 1,3-dienyl borate esters in the prior art, achieving high efficiency, environmental protection and operation Simple synthesis of axial chiral alkenyl borate, suitable for asymmetric allylation reactions.
Patent Information
- Application Number
- CN202410918285.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-10
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-07-10
AI Technical Summary
The prior art has failed to effectively develop efficient preparation of axial chiral 1,3-dienyl borates, especially axial chiral alkenyl borates containing phosphine or carboxylic acid esters, limiting asymmetric synthesis and novices. Preparation of phosphine olefin ligands.
Using a copper-palladium bicatalytic system, aryl bromides containing aryl groups, copper salts, palladium catalysts and ligands with diboron reagents under specific conditions The reaction is to produce axial chiral alkenyl borate with high corresponding selectivity phosphine or carboxylic acid esters.
The highly efficient synthesis of axial chiral alkenyl borates is achieved under mild conditions, which conforms to the green chemistry concept, is simple to operate, and can be used as an effective ligand in asymmetric allylation reactions.
Smart Images

Figure BDA0004935830570000041 
Figure BDA0004935830570000051 
Figure BDA0004935830570000061
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic synthesis, and in particular relates to a method for synthesizing an axially chiral alkenyl borate ester containing phosphine or carboxylate. Background Art
[0002] The enantioselective borylation of 1,3-enynes to synthesize new chiral organoboron compounds has attracted increasing attention from industry and academia, making it a valuable structural motif in asymmetric synthesis. However, previous studies have only demonstrated the feasibility of 1,2-difunctionalization or 1,4-difunctionalization of 1,3-enynes to deliver corresponding central chiral alkylboron compounds or axial chiral alkenylboron compounds. The method of synthesizing axially chiral 1,3-dienylborates by asymmetric catalytic 3,4-difunctionalization of the carbon-carbon triple bond of 1,3-enynes has not yet been developed. The synthesis of axially chiral 1,3-dienylborates containing phosphine will provide convenient conditions for the preparation of new chiral phosphine olefin ligands and has good application prospects. Summary of the invention
[0003] The object of the present invention is to overcome the defects of the prior art and provide a method for efficiently preparing axially chiral alkenyl borate containing phosphine or carboxylate.
[0004] The technical solution of the present invention is as follows:
[0005] The method for synthesizing phosphine-containing axial chiral alkenyl borate comprises the following steps:
[0006] (1) Add an aromatic 1,3-eneyne, a phosphine-containing aromatic bromide, a copper salt, palladium, and a ligand into a pressure-resistant sealed reaction vessel, add a diboron reagent and a base in a glove box, evacuate the air, fill with argon, add an organic solvent, and stir the reaction at 40° C. for 96 hours.
[0007] (2) taking the material obtained in step (1) out of the pressure-resistant sealed reaction vessel, cooling it to room temperature, adding ethyl acetate to elute it through a silica gel short column to obtain a crude product, and extracting the organic phase three times with 60° C. water; (3) drying the organic solvent in the organic phase obtained in step (2), purifying it with a silica gel column, and then eluting it with an eluent to obtain the phosphine-containing axial chiral alkenyl borate.
[0008] In a preferred embodiment of the present invention, the aromatic 1,3-enyne is one of an alkyl-substituted aromatic 1,3-enyne, an aromatic 1,3-enyne with no substitution on the benzene ring, an aromatic 1,3-enyne with substitution on the benzene ring, and an aromatic 1,3-enyne with multiple substitutions on the benzene ring.
[0009] In a preferred embodiment of the present invention, the phosphine-containing aryl bromide is a phosphorus-containing aryl bromide with no substitution on the benzene ring on the phosphine, a phosphorus-containing aryl bromide with a monosubstituted benzene ring on the phosphine, or a phosphorus-containing aryl bromide with a polysubstituted benzene ring on the phosphine.
[0010] In a preferred embodiment of the present invention, the copper salt is one of 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene copper salt and 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene copper salt.
[0011] A further preferred copper salt is 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene copper salt.
[0012] In a preferred embodiment of the present invention, the palladium catalyst is one of palladium acetate and palladium bromide.
[0013] A further preferred palladium catalyst is palladium acetate.
[0014] In a preferred embodiment of the present invention, the ligand is one of (R)-4-(anthracen-9-yl)-3-(tert-butyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole, (S)-3-(tert-butyl)-4-(2,6-dimethoxy-3,5-dimethylphenyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole, and (3aS,8aR)-2-(m-methyl)-3a,8a-dihydro-8H-indeno[1,2-d]dioxazole.
[0015] A further preferred ligand is (R)-4-(anthracen-9-yl)-3-(tert-butyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole.
[0016] In a preferred embodiment of the present invention, the diboron reagent is pinacol diboronate.
[0017] In a preferred embodiment of the present invention, the base is one of sodium tert-amylate and sodium tert-butoxide.
[0018] A further preferred base is sodium tert-amylate.
[0019] In a preferred embodiment of the present invention, the organic solvent is one of mesitylene and trifluorotoluene.
[0020] A further preferred organic solvent is mesitylene.
[0021] In a preferred embodiment of the present invention, the eluent is a mixed solution of petroleum ether and ethyl acetate.
[0022] Further preferably, the volume ratio of petroleum ether to ethyl acetate in the eluent is 10:1-3:1.
[0023] In a preferred embodiment of the present invention, in step (1), the ratio of the aromatic 1,3-enyne, aromatic bromide, copper salt, palladium, ligand, diboron reagent and base is 0.45mmol:0.3mmol:0.018mmol:0.024mmol:0.033mmol, 0.6mmol, 0.6mmol:3mL.
[0024] In a preferred embodiment of the present invention, the reaction time in step (1) is 96 hours.
[0025] The method for synthesizing an axially chiral alkenyl borate ester containing a carboxylate comprises the following steps:
[0026] (1) Add an aromatic 1,3-eneyne, an aromatic bromide containing a carboxylate, a copper salt, palladium, and a ligand into a pressure-resistant sealed reaction vessel, add a diboron reagent and a base in a glove box, evacuate the air, fill with argon, add an organic solvent, and stir the reaction at 15°C for 72 hours.
[0027] (2) taking the material obtained in step (1) out of the pressure-resistant sealed reaction vessel, cooling to room temperature, adding ethyl acetate to elute through a silica gel short column to obtain a crude product, and extracting the organic phase three times with 60° C. water; (3) drying the organic solvent in the organic phase obtained in step (2), purifying it with a silica gel column, and then eluting with an eluent to obtain the axially chiral alkenyl borate containing carboxylate.
[0028] In a preferred embodiment of the present invention, the aromatic 1,3-enyne is one of an alkyl-substituted aromatic 1,3-enyne, an aromatic 1,3-enyne with no substitution on the benzene ring, an aromatic 1,3-enyne with substitution on the benzene ring, and an aromatic 1,3-enyne with multiple substitutions on the benzene ring.
[0029] In a preferred embodiment of the present invention, the carboxylate-containing aryl bromide is a carboxylate-containing aryl bromide with no substitution on the benzene ring, a carboxylate-containing aryl bromide with a monosubstituted benzene ring, or a carboxylate-containing aryl bromide with no substitution on the naphthalene ring.
[0030] In a preferred embodiment of the present invention, the copper salt is one of 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene copper salt and 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene copper salt.
[0031] A further preferred copper salt is 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene copper salt.
[0032] In a preferred embodiment of the present invention, the palladium catalyst is one of palladium acetate and palladium bromide.
[0033] A further preferred palladium catalyst is palladium acetate.
[0034] In a preferred embodiment of the present invention, the ligand is one of (R)-4-(anthracen-9-yl)-3-(tert-butyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole, (S)-3-(tert-butyl)-4-(2,6-dimethoxy-3,5-dimethylphenyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole, and (3aS,8aR)-2-(m-methyl)-3a,8a-dihydro-8H-indeno[1,2-d]dioxazole.
[0035] A further preferred ligand is one of the ((S)-3-(tert-butyl)-4-(2,6-dimethoxy-3,5-dimethylphenyl)-2,3-dihydrobenzo[d][1,3]oxaphospholes.
[0036] In a preferred embodiment of the present invention, the diboron reagent is pinacol diboronate.
[0037] In a preferred embodiment of the present invention, the base is one of sodium tert-amylate and sodium tert-butoxide.
[0038] A further preferred base is sodium tert-amylate.
[0039] In a preferred embodiment of the present invention, the organic solvent is one of mesitylene, trifluorotoluene and methyl cyclopentyl ether.
[0040] A further preferred organic solvent is trifluorotoluene:methyl cyclopentyl ether in a ratio of 1:1.
[0041] In a preferred embodiment of the present invention, the eluent is a mixed solution of petroleum ether and ethyl acetate.
[0042] Further preferably, the volume ratio of petroleum ether to ethyl acetate in the eluent is 10:1-3:1.
[0043] In a preferred embodiment of the present invention, in the step (1), the ratio of the aromatic 1,3-enyne, carboxylic acid aromatic bromide, copper salt, palladium, ligand, diboron reagent and base is 0.3mmol:0.3mmol:0.012mmol:0.016mmol:0.022mmol, 0.4mmol, 0.4mmol:2mL.
[0044] In a preferred embodiment of the present invention, the reaction time in step (1) is 72 hours.
[0045] The beneficial effects of the present invention are:
[0046] 1. The present invention can carry out aromatic borylation reaction of 1,3-enyne containing aromatic group, aryl bromide containing phosphorus or carboxylate under mild conditions, with phosphine oxide cyclopentadiene as ligand and diboron reagent under the condition of copper-palladium dual catalysis to synthesize axial chiral alkenyl borate containing phosphine or carboxylate with high corresponding selectivity.
[0047] 2. Complying with the concept of green chemistry: The synthesis method of the present invention uses copper and palladium dual catalysts and is environmentally friendly.
[0048] 3. Simple operation: The synthetic method of the present invention is simple to operate, and axially chiral alkenyl borate can be obtained in one step.
[0049] 4. The axially chiral alkenyl borate containing phosphine synthesized by the present invention can be effectively converted into axially chiral phosphine-olefin, which can be used as a ligand in palladium-catalyzed asymmetric allylation reactions. DETAILED DESCRIPTION
[0050] In order to make the above features and advantages of the present invention more clearly understood, the following embodiments are given for detailed description. The methods of the present invention are all conventional methods in the art unless otherwise specified.
[0051] Embodiment 1:
[0052]
[0053] In a 10 ml Young's tube equipped with a magnetic, add 0.45 mmol (1E)-1-phenyl-1-octen-3-yne, 0.30 mmol aryl bromide containing phosphine oxide (1-bromonaphthol-2-diphenylphosphine as an example), 0.018 mmol 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene copper salt (CAS No. 873779-78-3), 0.024 mmol palladium acetate and 0.033 mmol (R)-4-(anthracen-9-yl)-3-(tert-butyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole (ligand L1). Place the sample in a nitrogen-filled glove box, add 0.6 mmol sodium tert-amyl alcohol, 0.6 mmol pinacol diboron and 3 ml ultra-dry mesitylene. Then seal the tube with a Teflon-lined screw cap and take it out of the glove box. The reaction mixture was then stirred at 40°C for 96h, and the reaction was terminated. Ethyl acetate was added and eluted through a silica gel short column to obtain a crude product, and the organic phase was extracted three times with 60°C water, the organic solvent was spin-dried, purified with a silica gel column, and then eluted with an eluent (petroleum ether: ethyl acetate = 10:1 volume ratio) to obtain the target product. The yield was 84% and the er value was 99.5:0.5.
[0054] (1E)-1-phenyl-1-octen-3-yne is a publicly reported raw material, reference: Guo, Z., Wen, H., Liu, G. & Huang, Z. Iron-catalyzed regio-and stereoselective hydrosilylation of 1,3-enynes to access 1,3-dienylsilanes. Org. Lett. 23, 2375-2379 (2021).
[0055] 1-Bronaphthol-2-diphenylphosphine is a publicly reported raw material, reference: Feng, J., Li, B., He, Y. & Gu, Z. Enantioselective synthesis of atropisomeric vinyl arene compounds by palladium catalysis: a carbene strategy. Angew. Chem. Int. Ed. 55, 2186-2190 (2016).
[0056] The universality of the substrate was studied under the standard conditions of the present invention to illustrate that the technical solution of the present invention has good functional group compatibility. The substrate range is as follows:
[0057]
[0058] The corresponding products are as follows:
[0059]
[0060] Embodiment 2:
[0061]
[0062] In a 10 ml Young's tube equipped with a magnetic electron, 0.45 mmol of 1,3-enyne (taking (1E)-1,6-diphenyl-1-hexene-3-yne as an example), 0.30 mmol of 1-bromonaphthol-2-diphenylphosphine, 0.018 mmol of 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene copper salt, 0.024 mmol of palladium acetate, and 0.033 mmol of (R)-4-(anthracen-9-yl)-3-(tert-butyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole were added. The sample was placed in a nitrogen-filled glove box, and 0.6 mmol of sodium tert-amyl alcohol, 0.6 mmol of biboric acid pinacol ester, and 3 ml of ultra-dry mesitylene were added. The tube was then sealed with a Teflon-lined screw cap and removed from the glove box. The reaction mixture was then stirred at 40°C for 96 h, and the reaction was completed. Ethyl acetate was added and eluted through a silica gel short column to obtain a crude product, and the organic phase was extracted three times with 60°C water, the organic solvent was spin-dried, purified with a silica gel column, and then eluted with an eluent (petroleum ether: ethyl acetate = 10:1 volume ratio) to obtain the target product. The yield was 81% and the er value was 99:1.
[0063] The universality of the substrate was studied under the standard conditions of the present invention to illustrate that the technical solution of the present invention has good functional group compatibility. The substrate range is as follows:
[0064]
[0065] The corresponding products are as follows:
[0066]
[0067] Embodiment 3:
[0068]
[0069] In a 10 ml Young's tube equipped with a magnetic electron, 0.45 mmol of 1,3-enyne (using (1E)-1,6-diphenyl-1-hexene-3-yne as an example), 0.30 mmol of 1-bromo-2-naphthoic acid oxetane ester, 0.018 mmol of 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene copper salt, 0.024 mmol of palladium acetate, and 0.033 mmol of (S)-3-(tert-butyl)-4-(2,6-dimethoxy-3,5-dimethylphenyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole (ligand L2) were added. The sample was placed in a nitrogen-filled glove box, and 0.6 mmol of sodium tert-amyl alcohol, 0.6 mmol of biboric acid pinacol ester, and 3 ml of ultra-dry mesitylene were added. The tube was then sealed with a Teflon-lined screw cap and removed from the glove box. The reaction mixture was then stirred at 15°C for 72h, and the reaction was terminated. Ethyl acetate was added and eluted through a silica gel short column to obtain a crude product, and the organic phase was extracted three times with 60°C water, the organic solvent was spin-dried, purified with a silica gel column, and then eluted with an eluent (petroleum ether: ethyl acetate = 10:1 volume ratio) to obtain the target product. The yield was 89% and the er value was 95.5:4.5.
[0070] The universality of the substrate was studied under the standard conditions of the present invention to illustrate that the technical solution of the present invention has good functional group compatibility. The substrate range is as follows:
[0071]
[0072] The corresponding products are as follows:
[0073]
[0074] Embodiment 4:
[0075]
[0076] In a 10 ml Young's tube equipped with a magnetic electron, 0.45 mmol (1E)-1-phenyl-1-octen-3-yne, 0.30 mmol 1-bromo-2-naphthoic acid oxetane ester, 0.018 mmol 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene copper salt, 0.024 mmol palladium acetate and 0.033 mmol (S)-3-(tert-butyl)-4-(2,6-dimethoxy-3,5-dimethylphenyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole (ligand L2) were added. The sample was placed in a nitrogen-filled glove box, and 0.6 mmol sodium tert-amyl alcohol, 0.6 mmol pinacol diboron and 3 ml ultra-dry mesitylene were added. The tube was then sealed with a Teflon-lined screw cap and removed from the glove box. The reaction mixture was then stirred at 15°C for 72 h to terminate the reaction. Ethyl acetate was added and eluted through a silica gel short column to obtain a crude product, and the organic phase was extracted three times with 60°C water, the organic solvent was spin-dried, purified with a silica gel column, and then eluted with an eluent (petroleum ether: ethyl acetate = 10:1 volume ratio) to obtain the target product. The yield was 89% and the er value was 95.5:4.5.
[0077] The universality of the substrate was studied under the standard conditions of the present invention to illustrate that the technical solution of the present invention has good functional group compatibility. The substrate range is as follows:
[0078]
[0079] The corresponding products are as follows:
[0080]
[0081] The literature sources of some of the raw materials used in the examples are as follows: 1Feng, J., Li, B., He, Y. & Gu, Z. Enantioselective synthesis of atropisomeric vinyl arene compounds by palladium catalysis: a carbene strategy. Angew. Chem. Int. Ed. 55, 2186-2190 (2016).
[0082] 2Ji,W.,Wu,H.-H.&Zhang,J.Axially chiral biaryl monophosphine oxidesenabled by palladium / wj-phos-catalyzed asymmetric suzuki–miyaura cross-coupling.ACS Catal.10,1548-1554(2020).
[0083] 3Zhu,Y.et al.Copper(I)-catalyzed synthesis of 1,3-enynes via couplingbetween vinyl halides and alkynes or domino coupling ofvinylhalides.Org.Biomol.Chem.9,7309-7312(2011).
[0084] 4Wu,Y.,Huang,M.,Mi,X.&Feng,Y.Discovery ofa novel palladium catalystfor the preparation ofenynes with a copper-and ligand-free sonogashirareaction.Synlett23,1257-1261(2012).
[0085] 5Zhang,H.&Larock,R.C.Synthesis ofannulatedγ-carbolines andheteropolycycles by the palladium-catalyzed intramolecular annulationofalkynes.J.Org.Chem.68,5132-5138(2003).
[0086] 6Wang,X.,Liu,Y.&Martin,R.Ni-catalyzed divergent cyclization / carboxylation ofunactivatedprimary and secondary alkyl halides withCO 2 .J.Am.Chem.Soc.137,6476-6479(2015)
[0087] 7Guo,Z.,Wen,H.,Liu,G.&Huang,Z.Iron-catalyzed regio-andstereoselective hydrosilylation of 1,3-enynes to access 1,3-dienylsilanes.Org.Lett.23,2375-2379(2021).
[0088] Substrates 1a, 1b, 1c, 1d, 1e, and 1h are reported in reference 1;
[0089] Substrates 1f, 1g, and 1i are reported in reference 2;
[0090] Substrate 2a is reported in reference 3;
[0091] Substrate 2c is reported in reference 4;
[0092] Substrate 2b is reported in reference 5;
[0093] Substrate 2d is reported in reference 6;
[0094] Substrates 2g and 2j are reported in reference 7.
[0095] The preparation methods of substrates 2e-2f, 2h-2i, 2m-2o are as follows:
[0096]
[0097] In a 100ml round-bottom flask, 0.08mmol tetrakis(triphenylphosphine palladium), 0.55mmol cuprous iodide, 5.0mmol aryl alkenyl bromide, 6.0mmol 1-hexyne were added and dissolved in 25ml diethylamine solvent. Stirring was carried out at room temperature for 12h, and the reaction was completed. The organic phase was extracted three times with water and ethyl acetate, dried over anhydrous sodium sulfate, and the organic solvent was spin-dried, purified with a silica gel column, and then rinsed with an eluent (petroleum ether: ethyl acetate 30:1 to 10:1) to obtain the target product.
[0098] The preparation method of substrates 1j-1m is as follows:
[0099]
[0100] In a 50ml round-bottom flask, add 4.0mmol 1-bromo-2-naphthalene, 4.8mmol N,N'-dicyclohexylcarboximide, 0.8mmol 4-methylaminopyridine, dissolve in 10ml dichloromethane, and then add 4.4mmol alcohol or phenol (taking 1j as an example, add p-methylphenol). Stir at room temperature for 12h, and the reaction is completed. Filter the reaction solution with a silica gel short column, wash with dichloromethane, spin dry, purify with a silica gel column, and then rinse with an eluent (petroleum ether: ethyl acetate 30:1 to 10:1) to obtain the target product.
[0101] Application Example 1:
[0102]
[0103] In a 10 ml Young's tube, 0.1 mmol of compound 1, 0.2 mmol of bis(p-nitrophenyl) phosphate (CAS No. 645-15-8), 1 ml of tetrahydrofuran solvent and 1 mmol of phenylsilane were added, and the mixture was reacted at 80°C for 8 h under argon protection. After the reaction, the solvent was dried by spin drying, and the crude product was eluted by silica gel chromatography (petroleum ether: ethyl acetate = 50:1 volume ratio) to obtain product 32 with a yield of 71% and an er value of 99.5:0.5.
[0104] The product 32 can be used as a ligand in palladium-catalyzed asymmetric allylation reactions.
[0105] In a 10 ml Young's tube, 0.004 mmol of ligand 32, 0.002 mmol of allylpalladium (II) chloride dimer (CAS No. 12012-95-2), and 0.016 mmol of lithium acetate were added and dissolved in ether. 0.4 mmol of N,O-bistrimethylsilylacetamide (CAS No. 10416-59-8) and 0.2 mmol of 1,3-diphenylallyl acetate (CAS No. 73930-97-9) were added. After stirring at room temperature for 30 minutes, 0.3 mmol of dimethyl malonate was added at -20°C and stirred for 10 hours. After the reaction was completed, the solvent was dried by spin drying, and the crude product was eluted by silica gel chromatography (petroleum ether: ethyl acetate = 10:1 volume ratio) to obtain product 33 with a yield of 90% and an er value of 71:29. This reaction proves that the prepared ligand has the function of being applied to palladium-catalyzed asymmetric allylation reaction.
[0106] The above substrate NMR data are as follows:
[0107] 1j
[0108] 1 H NMR (500 MHz, CDCl 3 ): δ8.47–8.44(m,1H),7.85–7.80(m,2H),7.69(d,J=8.5Hz,1H),7.66–7.57(m ,2H),7.40(d,J=8.1Hz,2H),7.22(d,J=7.8Hz,2H),5.41(s,2H),2.38(s,3H).
[0109] 13 C NMR (126 MHz, CDCl 3):δ167.37,138.43,135.29,132.59,132.42,131.33,129.43,128.78,128.68,128.30,128.24,128.22,127.92,125.98,122.88,67.70,21.38.1k
[0110] 1 H NMR(500 MHz,CDCl 3 ):δ8.46–8.43(m,1H),7.85–7.80(m,2H),7.67(d,J=8.4Hz,1H),7.66–7.62(m,1H),7.61–7.57(m,1H),7.01–6.96(m,2H),6.82(d,J=7.9 Hz,1H),5.98(s,2H),5.34(s,2H).
[0111] 13 C NMR(126 MHz,CDCl 3 ):δ167.34,147.98,147.94,135.31,132.43,131.27,129.32,128.68,128.32,128.28,128.25,127.96,125.93,122.87,122.78,109.44,108.43,101.34,67.74.
[0112] 1l
[0113] 1 H NMR(500 MHz,CDCl 3 ):δ8.49–8.40(m,1H),7.88–7.78(m,2H),7.67–7.63(m,2H),7.61–7.58(m,2H),7.44(t,J=1.7 Hz,1H),6.56(dd,J=0.8,2.0 Hz,1H),5.32(s,2H).
[0114] 13 C NMR(126 MHz,CDCl 3 ):δ167.37,143.63,142.05,135.30,132.40,131.23,128.67,128.30,128.28,128.26,127.96,125.88,122.83,120.17,110.88,59.17.
[0115] 1m
[0116] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ8.30(d,J=8.3 Hz,1H),7.62(dd,J=5.5,8.0 Hz,2H),7.55(d,J=8.5 Hz,1H),7.48–7.44(m,1H),7.42–7.38(m,1H),7.35(dd,J=1.1,2.9 Hz,1H),7.24(dd,J=2.9,5.0 Hz,1H),7.15(dd,J=1.3,5.0 Hz,1H),5.39(s,2H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0117] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ166.85,136.17,134.87,131.95,130.80,128.22,127.97,127.93,127.65,127.62,126.21,125.58,124.64,122.57,62.38.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0118] <h2 style=";text-align:left;direction:ltr"> 2e<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0119] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ7.49–7.39(m,1H),7.18(dt,J=3.6,7.8 Hz,3H),7.14(d,J=16.3 Hz,1H),6.10(dt,J=2.3,16.1 Hz,1H),2.41(td,J=2.2,7.1 Hz,2H),2.38(s,3H),1.63–1.57(m,2H),1.53–1.45(m,2H),1.08–0.88(m,3H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0120] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ137.82,135.65,130.54,128.21,126.26,124.92,110.00,92.71,80.14,31.01,22.18,19.90,19.47,13.77.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0121] <h2 style=";text-align:left;direction:ltr"> 2f<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0122] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3<h2 style=";text-align:left;direction:ltr">):δ7.18–7.14(m,1H),7.14–7.12(m,2H),7.07–6.98(m,1H),6.81(d,J=16.2 Hz,1H),6.12(dt,J=2.3,16.2 Hz,1H),2.35(td,J=2.1,7.0 Hz,2H),2.30(s,3H),1.58–1.49(m,2H),1.48–1.39(m,2H),0.92(t,J=7.3Hz,3H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0123] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ140.10,138.16,136.61,129.06,128.56,126.79,123.23,108.76,92.83,79.95,30.98,22.10,21.37,19.41,13.70.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0124] <h2 style=";text-align:left;direction:ltr"> 2h<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0125] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ7.26(s,4H),6.79(d,J=16.2 Hz,1H),6.12(dt,J=2.3,16.2 Hz,1H),2.36(td,J=2.3,7.0 Hz,2H),1.58–1.51(m,2H),1.49–1.40(m,2H),0.93(t,J=7.3 Hz,3H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0126] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ138.65,135.18,133.92,128.92,127.27,109.73,93.79,79.60,30.93,22.13,19.45,13.73.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0127] <h2 style=";text-align:left;direction:ltr"> 2i<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0128] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3<h2 style=";text-align:left;direction:ltr">):δ7.38–7.35(m,3H),7.16(d,J=7.9 Hz,2H),6.84(d,J=16.1 Hz,1H),6.14(dt,J=2.2,16.3 Hz,1H),2.39(td,J=2.2,7.1 Hz,2H),1.62–1.52(m,2H),1.50–1.45(m,2H),0.96(t,J=7.3 Hz,3H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0129] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ149.06,138.37,135.49,127.37,121.21,120.62(q,J=257.2 Hz),110.20,93.87,79.54,30.97,22.16,19.45,13.67.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0130] <h2 style=";text-align:left;direction:ltr"> 2k<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0131] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ7.37–7.34(m,2H),7.33–7.28(m,2H),7.27–7.23(m,1H),6.87(d,J=16.2 Hz,1H),6.14(dt,J=2.2,16.2 Hz,1H),3.22(t,J=6.9,6.9 Hz,2H),2.40(td,J=2.2,6.9 Hz,2H),2.02–1.92(m,2H),1.73–1.62(m,2H).<h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ140.46,136.56,128.78,128.44,126.19,108.69,91.86,80.51,32.59,29.55,18.76,6.36.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0132] <h2 style=";text-align:left;direction:ltr"> 2l<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0133] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3):δ7.96(d,J=1.1 Hz,1H),7.94(d,J=1.4 Hz,1H),7.51–7.47(m,1H),7.40(t,J=7.7 Hz,2H),7.32–7.30(m,2H),7.27–7.24(m,2H),7.22–7.18(m,1H),6.84(d,J=16.2 Hz,1H),6.13(dt,J=2.2,16.2 Hz,1H),3.08(t,J=7.2 Hz,2H),2.48(td,J=2.3,6.9 Hz,2H),1.98(p,J=7.1 Hz,2H).
[0134] 13 C NMR(126 MHz,CDCl 3 ):δ199.35,140.17,136.80,136.29,132.89,128.56,128.46,128.21,127.92,125.96,108.58,91.92,80.61,37.11,23.04,19.07.
[0135] 2m
[0136] 1 H NMR(500 MHz,CDCl 3 ):δ7.61–7.54(m,2H),7.51(d,J=8.3 Hz,2H),7.44–7.36(m,4H),7.35–7.27(m,1H),6.88(d,J=16.2Hz,1H),6.18(dt,J=2.1,16.3Hz,1H),2.45–2.27(m,2H),1.60–1.50(m,2H),1.49–1.39(m,2H),0.93(t,J=7.3Hz,3H).
[0137] 13 C NMR(126MHz,CDCl 3 ):δ140.98,140.59,139.57,135.72,128.90,127.50,127.38,126.99,126.58,109.04,93.41,79.99,31.00,22.14,19.50,13.76.
[0138] 2n
[0139] 1 H NMR(500MHz,CDCl 3):δ7.32–7.28(m,3H),7.28–7.26(m,1H),7.11–7.05(m,1H),7.01–6.99(m,1H),6.99–6.97(m,1H),6.94–6.89(m,2H),6.81(d,J=16.2Hz,1H),6.05(dt,J=16.1,2.2Hz,1H),2.35(td,J=7.0,2.3Hz,2H),1.57–1.49(m,2H),1.48–1.39(m,2H),0.92(t,J=7.3Hz,3H).
[0140] 13 C NMR(126MHz,CDCl 3 ):δ157.51,156.89,139.14,131.79,129.83,127.48,123.55,119.16,118.78,107.95,92.73,79.93,30.94,22.07,19.39,13.70.
[0141] HRMS(EI):calc’d for C 20 H 20 O 276.1514,found 276.1507.
[0142] 2o
[0143] 1 H NMR(500MHz,CDCl 3 ):δ8.17(d,J=7.9Hz,1H),7.88(dd,J=2.1,7.3Hz,1H),7.83(d,J=8.2Hz,1H),7.73(d,J=16.0Hz,1H),7.66(d,J=7.2Hz,1H),7.58–7.50(m,3H),7.47(m,1H),6.29(dt,J=2.3,15.8Hz,1H),2.48(td,J=2.3,7.1Hz,2H),1.69–1.63(m,2H),1.60–1.51(m,2H),1.03(t,J=7.3Hz,3H).
[0144] 13 C NMR(126MHz,CDCl 3): δ137.15,134.20,133.75,130.94,128.70,128.65,126.35,126.01,12 5.68,123.76,123.32,111.76,92.97,80.16,31.01,22.20,19.50,13.80.
[0145] The NMR data of the above products are as follows: 1
[0147] 1 H NMR (500 MHz, CDCl 3 ): δ7.92(d,J=8.5Hz,1H),7.81–7.76(m,2H),7.75(dd,J=1.4,4.7Hz,2H),7.74–7.69(m,2H),7.5 3–7.45(m,2H),7.44–7.36(m,2H),7.36–7.29(m,3H),7.28–7.23(m,2H),7.17(dd,J=4.2,11.8Hz ,3H),7.13–7.09(m,1H),7.10–7.06(m,2H),5.81(d,J=16.1Hz,1H),2.38–2.23(m,2H),1.73–1.5 9(m,1H),1.57–1.49(m,1H),1.49–1.40(m,2H),0.99(t,J=7.2Hz,3H),0.84(s,6H),0.60(s,6H).
[0148] 13 C NMR (126 MHz, CDCl 3):δ146.42,146.35,144.83,144.79,137.57,135.16,134.68,134.55,134.54,134.43,134.34,134.04,133.94,133.86,133.67,132.89,132.81,132.32,132.25,131.16,131.14,131.06,131.04,128.95,128.85,128.27,128.16,127.88,127.79,127.67,127.57,127.50,127.48,127.40,127.33,127.26,126.78,126.48,126.27,126.17,82.42,32.34,30.69,24.44,23.96,23.25,14.19.(Due to C-P coupling and thecomplexity ofthe spectrum,doublets in the aromatic region cannot be assignedand they are listed as singlets).
[0149] 31 P NMR(202 MHz,CDCl 3 ):δ28.90.
[0150] 11 B NMR(160 MHz,CDCl 3 ):δ28.12. 2
[0152] 1 H NMR(500 MHz,CDCl 3):δ7.94(d,J=8.5 Hz,1H),7.91–7.81(m,6H),7.67–7.62(m,1H),7.61–7.58(m,4H),7.54–7.51(m,3H),7.49–7.45(m,4H),7.45–7.41(m,3H),7.40–7.35(m,2H),7.22–7.16(m,3H),7.13(dd,J=6.9,13.2 Hz,3H),5.85(d,J=16.0 Hz,1H),2.41–2.26(m,2H),1.73–1.62(m,1H),1.61–1.50(m,1H),1.50–1.40(m,2H),0.99(t,J=7.3Hz,3H),0.90(s,6H),0.67(s,6H).
[0153] 13 C NMR(126 MHz,CDCl 3 ):δ146.54,146.47,144.81,144.77,144.04,143.93,140.51,140.38,137.70,134.71,134.17,134.08,133.90,133.46,133.38,133.03,132.94,132.86,132.51,129.01,128.90,128.47,128.14,128.04,127.96,127.59,127.50,127.39,126.82,126.73,126.63,126.57,126.48,126.38,82.55,32.45,30.84,24.54,24.16,23.32,14.22.(Due to C-P coupling and the complexity ofthe spectrum,doubletsin the aromatic region cannot be assigned and they are listed as singlets).
[0154] 31 P NMR(202 MHz,CDCl 3 ):δ28.39.
[0155] 11 B NMR(160 MHz,CDCl 3 ):δ28.96. 3
[0157] 1 H NMR(500 MHz,CDCl 3 ):δ7.91(d,J=8.6 Hz,1H),7.82–7.77(m,2H),7.76–7.66(m,4H),7.53–7.49(m,1H),7.46(dd,J=8.6,12.0 Hz,1H),7.43–7.39(m,1H),7.22(t,J=7.3 Hz,2H),7.18–7.13(m,2H),7.09(d,J=7.2 Hz,2H),7.02(td,J=2.0,8.8 Hz,2H),6.96(td,J=2.0,8.8 Hz,2H),5.77(d,J=16.1 Hz,1H),2.36–2.25(m,2H),1.69–1.60(m,1H),1.56–1.41(m,3H),0.99(t,J=7.2 Hz,3H),0.84(s,6H),0.60(s,6H).
[0158] 13 C NMR(126 MHz,CDCl 3 ):δ165.79,165.76,165.73,163.78,163.75,163.73,146.43,146.37,144.66,144.62,137.41,135.41,135.35,135.33,135.26,134.81,134.73,134.65,134.05,133.93,131.08,130.62,130.20,129.78,128.67,128.57,128.50,128.15,127.90,127.82,127.72,127.61,127.37,127.05,126.76,126.61,126.51,115.44,115.33,115.27,115.16,115.05,114.98,114.88,82.59,32.38,30.78,24.50,24.03,23.31,14.21.(Due to C-P and C-F coupling and the complexity ofthe spectrum,doublets inthe aromatic region cannot be assigned and they are listed as singlets).
[0159] 31 P NMR(202 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ27.52.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0160] <h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> B NMR(160 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ31.91.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 4<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0162] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ7.91(d,J=8.5 Hz,1H),7.79(d,J=8.0 Hz,1H),7.77(dd,J=2.1,8.7 Hz,1H),7.62(d,J=12.1 Hz,1H),7.57(d,J=12.3 Hz,1H),7.53(dd,J=8.6,11.8 Hz,1H),7.50–7.43(m,3H),7.42–7.36(m,1H),7.25–7.12(m,8H),7.11–7.07(m,2H),5.78(d,J=16.0 Hz,1H),2.32–2.28(m,2H),2.27(s,3H),2.16(s,3H),1.69–1.59(m,1H),1.57–1.39(m,3H),1.00(t,J=7.2 Hz,3H),0.84(s,6H),0.62(s,6H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0163] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3):δ146.31,146.24,144.76,144.72,137.91,137.82,137.69,137.48,137.38,135.12,134.59,134.57,134.30,134.16,134.06,133.77,133.64,133.29,133.22,132.99,132.92,132.01,131.99,131.89,131.87,130.13,130.05,129.60,129.49,129.41,129.11,129.01,128.55,128.32,128.18,127.72,127.59,127.53,127.49,127.43,127.40,126.80,126.42,126.26,126.16,82.43,32.44,30.67,24.46,24.13,23.32,21.53,21.35,14.23.(Due to C-P coupling and the complexity of thespectrum,doublets in the aromatic region cannot be assigned and they arelisted as singlets).
[0164] 31 P NMR(202 MHz,CDCl 3 ):δ29.02.
[0165] 11 B NMR(128 MHz,CDCl 3 ):δ30.62. 5
[0167] 1 H NMR(500 MHz,CDCl 3):δ7.90(d,J=8.5 Hz,1H),7.83–7.72(m,2H),7.56–7.45(m,2H),7.41–7.37(m,1H),7.36–7.30(m,2H),7.30–7.26(m,1H),7.26–7.22(m,2H),7.20–7.16(m,3H),7.15–7.09(m,4H),6.98–6.93(m,1H),6.84(dd,J=2.6,8.2 Hz,1H),5.80(d,J=16.0 Hz,1H),3.65(s,3H),3.59(s,3H),2.32(t,J=7.9 Hz,2H),1.69–1.59(m,1H),1.57–1.48(m,1H),1.48–1.40(m,2H),0.99(t,J=7.2 Hz,3H),0.83(s,6H),0.62(s,6H).
[0168] 13 C NMR(126 MHz,CDCl 3 ):δ159.29,159.17,159.08,158.96,146.38,146.31,144.44,144.40,137.63,136.18,135.96,135.37,135.15,134.60,134.07,133.97,133.51,128.95,128.88,128.76,128.31,128.22,128.06,127.49,127.41,127.40,126.75,126.45,126.35,126.25,125.26,125.18,124.61,124.53,117.84,117.75,117.33,117.31,117.28,117.26,117.20,117.12,82.48,55.24,55.16,32.36,30.67,24.37,24.05,23.26,14.21.(Due to C-P coupling and the complexity ofthe spectrum,doublets in thearomatic region cannot be assigned and they are listed as singlets). 31 P NMR(202 MHz,CDCl 3 ):δ28.94.
[0169] 11<h2 style=";text-align:left;direction:ltr">B NMR(128 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ30.15.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 6<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0171] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ7.93(d,J=8.5 Hz,1H),7.89–7.71(m,2H),7.60–7.39(m,7H),7.37–7.30(m,1H),7.28–7.24(m,1 H),7.23–7.17(m,3H),7.17–7.12(m,2H),7.12–7.08(m,2H),7.04(td,J=2.6,8.5 Hz,1H),5.78(d,J=16.0 Hz,1H),2.41–2.25(m,2H),1.71–1.61(m,1H),1.58–1.49(m,1H),1.49–1.41(m,2H),1.00(t,J=7.2 Hz,3H),0.84(s,6H),0.60(s,6H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0172] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3):δ163.45,163.32,163.18,161.47,161.33,161.19,146.93,146.86,144.21,144.17,137.56,137.52,137.40,137.12,137.08,136.74,136.70,136.31,136.27,134.84,134.82,134.03,133.95,130.09,130.03,129.98,129.92,129.67,129.61,129.56,129.50,128.55,128.49,128.42,128.01,127.97,127.67,127.65,127.38,127.02,126.87,126.78,126.66,126.55,126.17,119.86,119.78,119.69,119.60,119.20,119.11,119.02,118.94,118.73,118.62,118.57,118.46,82.70,32.32,30.72,24.44,23.97,23.34,14.21.(Due to C-P and C-F coupling,and the complexity ofthespectrum,doublets in the aromatic region cannot be assigned and they arelisted as singlets).
[0173] 31 P NMR(202 MHz,CDCl 3 ):δ26.92.
[0174] 11 B NMR(128 MHz,CDCl 3 ):δ29.79. 7 1 H NMR(500 MHz,CDCl 3):δ7.94(d,J=8.6 Hz,1H),7.82(d,J=8.2 Hz,2H),7.74(dt,J=1.7,1.7,7.2 Hz,1H),7.72(dt,J=1.7,7.5 Hz,1H),7.66–7.60(m,1H),7.60–7.55(m,1H),7.55–7.50(m,1H),7.49–7.40(m,3H),7.34–7.31(m,1H),7.28(td,J=3.3,7.8 Hz,1H),7.24–7.19(m,3H),7.19–7.11(m,4H),5.81(d,J=16.1 Hz,1H),2.35–2.22(m,2H),1.73–1.60(m,1H),1.59–1.49(m,1H),1.49–1.42(m,2H),1.01(t,J=7.2 Hz,3H),0.85(s,6H),0.62(s,6H).
[0176] 13 C NMR(126 MHz,CDCl 3 ):δ146.76,146.69,143.94,143.90,137.30,137.05,136.79,136.24,135.99,134.87,134.85,134.75,134.63,134.39,134.25,134.01,133.91,132.61,132.52,131.95,131.86,131.67,131.65,131.61,131.59,130.94,130.87,130.40,130.33,129.51,129.41,129.17,129.07,128.50,128.43,128.41,127.98,127.83,127.73,127.67,127.36,126.92,126.83,126.78,126.67,126.07,82.67,32.35,30.65,24.42,24.14,23.33,14.19,136.54–136.44(m).(Due to C-P coupling and the complexity ofthe spectrum,doublets in the aromatic region cannot be assigned and they arelisted as singlets).
[0177] 31P NMR(202 MHz,CDCl 3 ):δ26.74.
[0178] 11 B NMR(128 MHz,CDCl 3 ):δ30.79. 8
[0180] 1 H NMR(500 MHz,CDCl 3 ):δ7.93(d,J=8.5 Hz,1H),7.80(d,J=8.1 Hz,1H),7.78(dd,J=2.0,8.7 Hz,1H),7.54(dd,J=8.6,11.8 Hz,1H),7.51–7.46(m,1H),7.42–7.37(m,1H),7.34(t,J=12.0 Hz,4H),7.24–7.16(m,3H),7.15–7.08(m,3H),7.06(s,1H),6.91(s,1H),5.77(d,J=16.0 Hz,1H),2.33(t,J=7.9 Hz,2H),2.26(s,6H),2.14(s,6H),1.71–1.60(m,1H),1.59–1.52(m,1H),1.52–1.44(m,2H),1.02(t,J=7.3 Hz,3H),0.84(s,6H),0.65(s,6H).
[0181] 13 C NMR(126 MHz,CDCl 3):δ146.26,146.19,144.37,144.34,137.66,137.33,137.27,137.23,137.17,135.08,134.51,134.49,134.26,134.19,134.09,133.55,133.43,132.91,132.82,130.29,130.22,130.06,129.98,129.11,129.01,128.66,128.21,127.84,127.41,127.36,127.29,126.67,126.26,126.15,126.05,82.32,32.44,30.52,24.37,24.27,23.27,21.39,21.23,14.20.(Due to C-P coupling and the complexity of thespectrum,doublets in the aromatic region cannot be assigned and they arelisted as singlets).
[0182] 31 P NMR(202 MHz,CDCl 3 ):δ28.79.
[0183] 11 B NMR(128 MHz,CDCl 3 ):δ30.19. 9
[0185] 1 H NMR(500 MHz,CDCl 3):δ7.91(d,J=8.5 Hz,1H),7.80(d,J=8.0 Hz,1H),7.76(dd,J=1.9,8.6 Hz,1H),7.68(d,J=1.7 Hz,1H),7.66(d,J=1.7 Hz,1H),7.59(d,J=1.7Hz,1H),7.57(d,J=1.7 Hz,1H),7.54(s,1H),7.49–7.43(m,2H),7.41–7.34(m,2H),7.20(d,J=16.0 Hz,1H),7.13(t,J=7.3 Hz,2H),7.07(t,J=7.2 Hz,1H),6.98(d,J=7.2 Hz,2H),5.67(d,J=16.0 Hz,1H),2.54–2.47(m,1H),2.46–2.37(m,1H),1.77–1.67(m,1H),1.64–1.55(m,1H),1.55–1.46(m,2H),1.29(s,18H),1.17(s,18H),1.03(t,J=7.2 Hz,3H),0.82(s,6H),0.66(s,6H).
[0186] 13 C NMR(126 MHz,CDCl 3 ):δ150.12,150.03,150.00,149.90,146.99,146.93,143.79,143.75,137.93,134.39,134.38,134.31,134.22,134.19,133.71,133.38,132.89,132.85,129.29,128.95,128.85,128.54,128.48,128.08,127.92,127.64,127.36,127.11,127.05,126.78,126.72,126.35,126.14,126.06,126.01,125.82,125.72,125.24,125.03,82.14,32.38,31.48,31.34,30.63,24.40,24.30,23.27,14.24.(Due to C-P couplingand the complexity of the spectrum,doublets in the aromatic region cannot beassigned and they are listed as singlets).
[0187] 31 P NMR(202 MHz,CDCl 3 ):δ28.83.
[0188] 11 B NMR(128 MHz,CDCl 3 ):δ28.48. 10
[0190] 1 H NMR(500 MHz,CDCl 3 ):δ7.86(d,J=8.5 Hz,1H),7.83–7.75(m,6H),7.55–7.50(m,2H),7.48–7.44(m,1H),7.43–7.35(m,6H),7.34–7.27(m,5H),7.24(d,J=4.6 Hz,1H),7.22–7.20(m,2H),7.18–7.14(m,1H),7.12–7.09(m,2H),5.84(d,J=16.0 Hz,1H),3.09–3.00(m,1H),2.96–2.87(m,1H),2.80–2.72(m,1H),2.72–2.63(m,1H),0.89(s,6H),0.62(s,6H).
[0191] 13 C NMR(126 MHz,CDCl 3 ):δ146.48,146.42,145.79,145.75,142.90,137.48,135.20,134.54,134.38,134.25,133.99,133.89,133.71,132.88,132.80,132.32,132.25,131.26,131.10,128.89,128.79,128.29,128.04,127.94,127.85,127.78,127.68,127.52,127.48,127.34,127.22,126.84,126.48,126.31,126.21,125.72,82.51,36.03,32.97,24.53,24.01.(Due to C-P coupling and the complexity of the spectrum,doubletsin the aromatic region cannot be assigned and they are listed as singlets). <h2 style=";text-align:left;direction:ltr">
[0192] <h2 style=";text-align:left;direction:ltr"> 31 <h2 style=";text-align:left;direction:ltr"> P NMR(202 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ29.26.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0193] <h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> B NMR(160 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ27.67.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 11<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0195] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ7.89(d,J=8.5 Hz,1H),7.80(d,J=8.0 Hz,1H),7.76(dd,J=2.2,8.6 Hz,1H),7.75–7.67(m,4H),7.53–7.44(m,2H),7.44–7.34(m,5H),7.30(td,J=1.3,7.4,7.4 Hz,1H),7.23(td,J=2.8,7.2,7.4 Hz,2H),7.17(dd,J=6.4,7.9Hz,2H),7.15–7.10(m,1H),7.08–7.04(m,2H),5.71(d,J=16.0Hz,1H),3.91–3.83(m,1H),3 .80–3.70(m,1H),2.71–2.64(m,1H),2.59–2.53(m,1H),2.23–2.13(m,1H),2.13–2.06(m,1H),0.86(s,6H),0.58(s,6H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0196] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3):δ146.75,146.71,146.70,146.63,137.41,135.53,134.70,134.67,134.58,134.56,134.07,134.00,133.97,133.19,132.75,132.68,132.28,132.21,131.35,131.33,131.15,131.13,128.87,128.77,128.29,128.08,127.98,127.96,127.87,127.62,127.60,127.58,127.11,126.94,126.66,126.25,126.15,82.61,45.93,33.01,27.83,24.57,23.91.(Due to C-P coupling and the complexity of thespectrum,doublets in the aromatic region cannot be assigned and they arelisted as singlets).
[0197] 31 P NMR(202 MHz,CDCl 3 ):δ29.08.
[0198] 11 B NMR(128 MHz,CDCl 3 ):δ30.82. 12
[0200] 1 H NMR(500 MHz,CDCl 3):δ7.91(d,J=8.5 Hz,1H),7.80(d,J=8.1 Hz,1H),7.78–7.72(m,3H),7.71(d,J=7.0 Hz,1H),7.54–7.47(m,2H),7.46–7.41(m,1H),7.41–7.37(m,1H),7.37–7.30(m,3H),7.32–7.22(m,2H),7.20(t,J=7.3Hz,2H),7.17–7.12(m,2H),7.12–7.07(m,2H),5.81(d,J=16.0 Hz,1H),2.36–2.21(m,2H),1.75–1.59(m,1H),1.59–1.45(m,1H),1.45–1.37(m,4H),0.94(t,J=7.2,3H),0.85(s,6H),0.61(s,6H).
[0201] 13 C NMR(126 MHz,CDCl 3 ):δ146.47,146.40,144.86,144.82,137.68,135.23,134.85,134.63,134.40,134.12,134.03,133.75,132.99,132.91,132.43,132.36,131.21,131.19,131.11,131.09,129.05,128.95,128.37,128.34,128.30,127.93,127.84,127.72,127.62,127.54,127.46,127.39,126.86,126.51,126.34,126.24,82.50,32.47,30.99,29.82,24.51,24.05,22.63,14.29.(Due to C-P coupling and the complexity of thespectrum,doublets in the aromatic region cannot be assigned and they arelisted as singlets).
[0202] 31 P NMR(202 MHz,CDCl 3 ):δ28.94.
[0203] 11 B NMR(128 MHz,CDCl 3):δ32.19. 13
[0205] 1 H NMR(500 MHz,CDCl 3 ):δ7.93–7.88(m,1H),7.78(d,J=8.0 Hz,1H),7.77–7.68(m,5H),7.50–7.44(m,2H),7.46–7.39(m,1H),7.41–7.37(m,1H),7.36–7.29(m,3H),7.28–7.22(m,3H),7.17(t,J=7.3,7.3 Hz,2H),7.14–7.10(m,1H),7.10–7.07(m,2H),5.80(d,J=16.0 Hz,1H),3.51(t,J=6.9,6.9 Hz,2H),2.50–2.41(m,1H),2.41–2.32(m,1H),2.02(p,J=7.0,7.0,7.1,7.1 Hz,2H),1.85–1.69(m,2H),0.85(s,6H),0.59(s,6H).
[0206] 13 C NMR(126 MHz,CDCl 3 ):δ146.53,146.46,145.91,145.87,137.41,135.25,134.50,134.43,134.20,134.00,133.90,133.69,132.76,132.68,132.22,132.15,131.19,131.17,131.06,131.04,128.84,128.74,128.24,128.02,127.94,127.85,127.78,127.69,127.50,127.09,126.83,126.53,126.21,126.11,82.49,34.20,33.06,29.69,28.49,24.48,23.90.(Due to C-P coupling and the complexity ofthe spectrum,doubletsin the aromatic region cannot be assigned and they are listed as singlets). 31 PNMR(202 MHz,CDCl 3 ):δ28.92.
[0207] 11 B NMR(128 MHz,CDCl 3 ):δ31.47. 14
[0209] 1 H NMR(500 MHz,CDCl 3 ):δ7.91(d,J=8.5 Hz,1H),7.85–7.68(m,6H),7.57–7.46(m,2H),7.46–7.35(m,3H),7.35–7.27(m,5H),7.13(t,J=7.4 Hz,1H),7.07(td,J=1.2,7.4 Hz,1H),7.02(d,J=15.9 Hz,1H),6.98(d,J=7.4 Hz,1H),6.06(d,J=16.0 Hz,1H),2.28–2.16(m,2H),1.85(s,3H),1.68–1.55(m,1H),1.55–1.47(m,1H),1.46–1.38(m,2H),0.98(t,J=7.2 Hz,3H),0.86(s,6H),0.62(s,6H).
[0210] 13 C NMR(126 MHz,CDCl 3 ):δ146.47,146.41,145.26,145.22,136.67,136.26,135.16,135.01,134.56,134.55,134.34,134.19,133.99,133.89,133.05,132.98,132.40,132.33,131.86,131.20,131.18,131.12,131.09,130.24,129.59,129.06,128.97,128.45,127.91,127.82,127.67,127.62,127.57,127.53,127.50,127.38,126.45,126.35,126.25,125.86,125.50,82.50,32.40,30.72,24.51,24.03,23.32,19.58,14.24.(Due to C-Pcoupling and the complexity of the spectrum,doublets in the aromatic regioncannot be assigned and they are listed as singlets).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0211] <h2 style=";text-align:left;direction:ltr"> 31 <h2 style=";text-align:left;direction:ltr"> P NMR(202 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ28.85.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0212] <h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> B NMR(128 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ30.30.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 15<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0214] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ7.91(d,J=8.6 Hz,1H),7.79(d,J=8.1 Hz,1H),7.78–7.69(m,5H),7.54–7.47(m,2H),7.46–7.42(m,1H),7.41–7.31(m,4H),7.28(td,J=2.8,7.6Hz,2H),7.14(d,J=16.0 Hz,1H),7.10(t,J=7.6 Hz,1H),6.96(d,J=7.6 Hz,1H),6.93(d,J=7.8 Hz,1H),6.86(s,1H),5.78(d,J=16.0 Hz,1H),2.34–2.22(m,5H),1.70–1.57(m,1H),1.57–1.48(m,1H),1.47–1.40(m,2H),0.99(t,J=7.2 Hz,3H),0.85(s,6H),0.61(s,6H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0215] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3):δ146.53,146.46,144.95,144.92,137.78,137.56,135.22,134.76,134.63,134.61,134.39,134.11,134.01,133.95,132.98,132.90,132.44,132.36,131.21,131.19,131.09,131.07,129.02,128.92,128.29,128.22,128.20,128.17,127.94,127.84,127.72,127.62,127.55,127.52,127.38,127.34,126.53,126.32,126.22,82.49,32.40,30.72,24.49,24.02,23.30,21.39,14.23.(Due to C-P coupling and thecomplexity ofthe spectrum,doublets in the aromatic region cannot be assignedand they are listed as singlets).
[0216] 31 P NMR(202 MHz,CDCl 3 ):δ29.13.
[0217] 11 B NMR(128 MHz,CDCl 3 ):δ29.59. 16
[0219] 1 H NMR(500 MHz,CDCl 3 ):δ7.90(d,J=8.6 Hz,1H),7.81–7.67(m,6H),7.58–7.46(m,2H),7.45–7.41(m,1H),7.41–7.34(m,2H),7.34–7.26(m,4H),7.06(d,J=16.0 Hz,1H),7.03–6.96(m,4H),5.79(d,J=16.0 Hz,1H),2.29(s,3H),2.27–2.19(m,2H),1.68–1.56(m,1H),1.56–1.46(m,1H),1.46–1.38(m,2H),0.98(t,J=7.2 Hz,3H),0.84(s,6H),0.61(s,6H).
[0220] 13 C NMR(126 MHz,CDCl 3 ):δ146.51,146.44,145.08,145.04,137.37,135.20,134.92,134.63,134.62,134.37,134.14,134.09,134.04,133.81,133.03,132.95,132.48,132.40,131.20,131.18,131.12,131.10,129.11,129.07,128.97,128.29,127.92,127.82,127.70,127.60,127.58,127.52,127.46,126.81,126.50,126.33,126.23,82.48,32.42,30.72,24.51,24.05,23.32,21.35,14.25.(Due to C-P coupling and the complexityof the spectrum,doublets in the aromatic region cannot be assigned and theyare listed as singlets).
[0221] 31 P NMR(202 MHz,CDCl 3 ):δ29.11.
[0222] 11 B NMR(128 MHz,CDCl 3 ):δ31.89. 17
[0224] 1 H NMR(500 MHz,CDCl 3):δ7.91(d,J=8.5 Hz,1H),7.80(d,J=8.0 Hz,1H),7.80–7.66(m,5H),7.51–7.45(m,2H),7.45–7.39(m,2H),7.37–7.31(m,3H),7.29–7.25(m,2H),7.19–7.12(m,3H),6.99(d,J=8.5 Hz,2H),5.73(d,J=16.0Hz,1H),2.43–2.25(m,2H),1.71–1.61(m,1H),1.56–1.40(m,3H),0.99(t,J=7.2 Hz,3H),0.84(s,6H),0.59(s,6H).
[0225] 13 C NMR(126 MHz,CDCl 3 ):δ146.37,146.31,144.53,144.49,136.23,135.23,134.67,134.65,134.41,134.06,133.97,133.86,132.92,132.84,132.31,132.25,131.26,131.24,131.16,131.14,129.00,128.90,128.86,128.47,128.18,128.01,127.97,127.91,127.75,127.65,127.62,127.59,127.36,127.21,126.61,126.36,126.26,82.54,32.37,30.78,24.48,24.00,23.30,14.23.(Due to C-P coupling and the complexity of thespectrum,doublets in the aromatic region cannot be assigned and they arelisted as singlets).
[0226] 31 P NMR(202 MHz,CDCl 3 ):δ28.87.
[0227] 11 B NMR(128 MHz,CDCl 3 ):δ29.78. 18
[0229] 1H NMR(500 MHz,CDCl 3 ):δ8.09(d,J=8.5 Hz,1H),7.98(d,J=8.1 Hz,1H),7.98–7.84(m,5H),7.71–7.63(m,2H),7.60(dd,J=8.1,15.5 Hz,2H),7.55–7.48(m,3H),7.48–7.41(m,2H),7.37(d,J=16.0 Hz,1H),7.26(d,J=8.7 Hz,2H),7.21(d,J=8.4 Hz,2H),5.93(d,J=16.0 Hz,1H),2.61–2.42(m,2H),1.89–1.79(m,1H),1.75–1.57(m,3H),1.17(t,J=7.2 Hz,3H),1.02(s,6H),0.77(s,6H).
[0230] 13 C NMR(126 MHz,CDCl 3 ):δ148.34,146.41,146.34,144.46,144.42,136.49,135.23,134.67,134.66,134.57,134.40,134.07,133.98,133.75,132.90,132.82,132.29,132.21,131.98,131.29,131.28,131.16,131.15,129.18,129.00,128.90,128.11,128.03,127.95,127.78,127.68,127.66,127.61,127.29,127.17,126.65,126.37,126.27,120.85,82.56,32.38,30.81,24.48,23.99,23.31,14.23.(Due to C-P coupling and thecomplexity of the spectrum,doublets in the aromatic region cannot be assignedand they are listed as singlets).
[0231] 31 P NMR(202 MHz,CDCl 3 ):δ28.94.
[0232] 11 B NMR(128 MHz,CDCl3 ):δ31.29. 19
[0234] 1 H NMR(500 MHz,CDCl 3 ):δ8.01–7.92(m,2H),7.90–7.80(m,2H),7.70(d,J=16.0Hz,1H),7.53–7.50(m,1H),7.46–7.42(m,1H),7.33–7.24(m,2H),7.23(t,J=7.6 Hz,2H),7.20–7.11(m,1H),5.89(d,J=16.0 Hz,1H),5.66–5.49(m,1H),4.99–4.87(m,2H),4.83–4.62(m,2H),2.71(t,J=7.7 Hz,2H),1.67–1.57(m,2H),1.56–1.47(m,2H),1.03(t,J=7.3Hz,3H),0.73(s,6H),0.70(s,6H).
[0235] 13 C NMR(126 MHz,CDCl 3 ):δ166.82,145.25,142.70,137.71,135.04,133.47,133.21,128.56,128.30,127.67,127.54,127.41,127.27,126.97,126.72,126.62,125.75,82.67,77.84,77.56,68.33,32.52,30.43,24.28,24.16,23.03,14.29.
[0236] 11 B NMR(128 MHz,CDCl 3 ):δ30.71. 20
[0238] 1 H NMR(500 MHz,CDCl 3):δ7.99(d,J=8.6 Hz,1H),7.91(d,J=8.6 Hz,1H),7.87(d,J=8.7 Hz,1H),7.85(d,J=8.4 Hz,1H),7.73(d,J=15.9 Hz,1H),7.52(t,J=7.3 Hz,1H),7.44(t,J=7.6 Hz,1H),7.29(d,J=7.5 Hz,2H),7.23(t,J=7.6 Hz,2H),7.16(t,J=7.2 Hz,1H),5.91(d,J=15.9 Hz,1H),5.62–5.46(m,1H),4.97–4.89(m,2H),4.75–4.66(m,2H),3.81–3.65(m,2H),2.95–2.75(m,2H),2.18–2.03(m,2H),0.73(s,6H),0.68(s,6H).
[0239] 13 C NMR(126 MHz,CDCl 3 ):δ166.52,147.17,142.62,137.48,135.09,134.06,133.35,128.12,127.90,127.64,127.41,127.20,126.90,126.72,126.70,125.73,77.87,77.59,68.43,45.17,33.12,27.61,24.28,24.23.
[0240] 11 B NMR(128 MHz,CDCl 3 ):δ31.02. 21
[0242] 1 H NMR(500 MHz,CDCl 3<h2 style=";text-align:left;direction:ltr">):δ7.96(dd,J=5.2,8.6 Hz,2H),7.87–7.80(m,2H),7.64(d,J=16.0 Hz,1H),7.51(t,J=7.1 Hz,1H),7.43(t,J=7.2 Hz,1H),7.17(d,J=8.1 Hz,2H),7.04(d,J=8.1 Hz,2H),5.86(d,J=16.0 Hz,1H),5.62–5.42(m,1H),4.91(dt,J=7.0,10.0 Hz,2H),4.76–4.68(m,2H),2.69(t,J=7.7 Hz,2H),2.28(s,3H),1.66–1.56(m,2H),1.56–1.46(m,2H),1.02(t,J=7.2 Hz,3H),0.72(s,6H),0.69(s,6H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0243] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ166.90,145.49,142.83,137.60,135.04,134.94,133.51,133.24,129.29,128.37,127.52,127.51,127.39, 127.21,126.65,126.58,126.13,125.75,77.83,77.59,68.30,32.55,30.41,24.28,24.16,23.04,21.30,14.30.<h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> B NMR(128MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ30.41.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 22<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0245] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3):δ7.96(d,J=8.6 Hz,1H),7.92(d,J=8.5 Hz,1H),7.88–7.82(m,2H),7.65(d,J=16.0 Hz,1H),7.55–7.49(m,1H),7.47–7.40(m,1H),7.19(s,4H),5.82(d,J=15.9 Hz,1H),5.58–5.50(m,1H),4.95–4.87(m,2H),4.78–4.66(m,2H),2.75–2.60(m,2H),1.64–1.56(m,2H),1.54–1.45(m,2H),1.02(t,J=7.2 Hz,3H),0.72(s,6H),0.69(s,6H).
[0246] 13 C NMR(126 MHz,CDCl 3 ):δ166.71,144.84,142.47,136.22,135.05,133.38,133.18,131.76,128.70,128.18,127.88,127.60,127.46,127.36,126.71,125.72,82.74,77.86,77.50,68.40,32.48,30.46,24.29,24.15,23.01,14.28.
[0247] 11 B NMR(128 MHz,CDCl 3 ):δ30.47. 23
[0249] 1 H NMR(500 MHz,CDCl 3):δ7.97(d,J=8.5 Hz,1H),7.95(d,J=8.6 Hz,1H),7.84(t,J=8.1 Hz,2H),7.55–7.47(m,3H),7.44(t,J=7.2 Hz,1H),7.15(t,J=7.5Hz,1H),7.08(t,J=7.0,7.0 Hz,1H),6.99(d,J=7.4 Hz,1H),6.11(d,J=15.8 Hz,1H),5.61–5.50(m,1H),4.93(q,J=6.9 Hz,2H),4.77–4.70(m,2H),2.68(t,J=7.7 Hz,2H),1.82(s,3H),1.62–1.55(m,2H),1.54–1.45(m,2H),1.01(t,J=7.3Hz,3H),0.73(s,6H),0.70(s,6H).
[0250] 13 C NMR(126 MHz,CDCl 3 ):δ167.02,145.57,142.77,136.97,135.92,134.99,133.39,131.79,130.28,128.39,128.34,127.57,127.50,127.42,127.27,126.54,126.16,125.71,125.50,82.70,77.87,77.61,68.36,32.54,30.45,24.33,24.18,23.06,19.46,14.30.
[0251] 11 B NMR(128 MHz,CDCl 3 ):δ31.18. 24
[0253] 1 H NMR(500 MHz,CDCl 3):δ7.95(t,J=9.0 Hz,2H),7.88–7.80(m,2H),7.67(d,J=16.0 Hz,1H),7.51(t,J=7.3 Hz,1H),7.45–7.41(m,1H),7.17–7.08(m,2H),7.06(s,1H),6.97(d,J=6.8 Hz,1H),5.86(d,J=16.0 Hz,1H),5.60–5.49(m,1H),4.96–4.86(m,2H),4.77–4.62(m,2H),2.70(t,J=7.5 Hz,2H),2.26(s,3H),1.65–1.57(m,2H),1.56–1.47(m,2H),1.03(t,J=7.2 Hz,3H),0.72(s,6H),0.69(s,6H). 13 C NMR(126 MHz,CDCl 3 ):δ166.86,145.34,142.77,138.10,137.63,135.05,133.48,133.41,128.50,128.47,128.34,127.63,127.54,127.53,127.40,127.25,126.79,126.62,125.76,123.72,82.66,77.85,77.60,68.32,32.54,30.42,24.29,24.16,23.03,21.40,14.30.
[0254] 11 B NMR(128 MHz,CDCl 3 ):δ30.83. 25
[0256] 1 H NMR(500 MHz,CDCl 3):δ7.97(t,J=9.0 Hz,2H),7.90–7.82(m,2H),7.74(d,J=16.0 Hz,1H),7.57–7.54(m,2H),7.54–7.51(m,1H),7.48(d,J=8.3 Hz,2H),7.45(t,J=7.1 Hz,1H),7.41(t,J=7.7 Hz,2H),7.35(d,J=8.3 Hz,2H),7.31(t,J=7.4 Hz,1H),5.92(d,J=16.0 Hz,1H),5.61–5.46(m,1H),5.03–4.87(m,2H),4.83–4.60(m,2H),2.72(t,J=7.7 Hz,2H),1.66–1.59(m,2H),1.57–1.48(m,2H),1.04(t,J=7.2 Hz,3H),0.73(s,6H),0.70(s,6H).
[0257] 13 C NMR(126 MHz,CDCl 3 ):δ166.85,145.30,142.70,140.78,140.38,136.80,135.08,133.49,132.74,128.88,128.32,127.58,127.45,127.39,127.32,127.26,127.18,127.06,126.98,126.68,125.79,77.88,77.61,68.37,32.57,30.49,24.31,24.18,23.07,14.32.
[0258] 11 B NMR(128 MHz,CDCl 3 ):δ30.15. 26
[0260] 1 H NMR(500 MHz,CDCl 3):δ7.95(dd,J=6.3,8.2 Hz,2H),7.88–7.79(m,2H),7.60(d,J=16.0 Hz,1H),7.50(t,J=7.4 Hz,1H),7.43(t,J=7.6 Hz,1H),7.34–7.24(m,2H),7.23(d,J=8.1 Hz,2H),7.06(t,J=7.4 Hz,1H),6.95(d,J=7.7 Hz,2H),6.87(d,J=8.7Hz,2H),5.85(d,J=16.0 Hz,1H),5.60–5.42(m,1H),5.04–4.86(m,2H),4.76–4.67(m,2H),2.68(t,J=6.9 Hz,2H),1.66–1.56(m,2H),1.55–1.44(m,2H),1.01(t,J=7.3 Hz,3H),0.72(s,6H),0.68(s,6H).
[0261] 13 C NMR(126 MHz,CDCl 3 ):δ166.81,157.20,156.88,145.31,142.74,135.03,133.46,132.99,132.41,129.82,128.29,128.10,127.55,127.53,127.41,127.25,126.63,126.21,125.73,123.38,118.98,118.92,82.64,77.89,77.54,68.34,32.53,30.40,24.28,24.16,23.02,14.30.
[0262] 11 B NMR(128 MHz,CDCl 3 ):δ31.05. 27
[0264] 1 H NMR(500 MHz,CDCl 3):δ7.99(dd,J=3.5,8.1 Hz,2H),7.89(d,J=8.5 Hz,1H),7.86(d,J=8.0 Hz,1H),7.82(d,J=15.9 Hz,1H),7.77–7.71(m,2H),7.66–7.60(m,2H),7.56–7.50(m,1H),7.49(s,1H),7.47–7.43(m,1H),7.39–7.36(m,2H),6.06(d,J=15.9 Hz,1H),5.60–5.52(m,1H),4.96–4.86(m,2H),4.78–4.69(m,2H),2.75(t,J=7.7 Hz,2H),1.69–1.59(m,2H),1.59–1.48(m,2H),1.05(t,J=7.3 Hz,3H),0.74(s,6H),0.71(s,6H).
[0265] 13 C NMR(126 MHz,CDCl 3 ):δ166.86,145.31,142.73,135.21,135.10,133.67,133.52,133.33,133.10,128.33,128.20,128.01,127.71,127.60,127.59,127.49,127.33,127.32,127.14,126.70,126.30,125.93,125.79,123.54,82.71,77.85,77.58,68.39,32.56,30.52,24.32,24.19,23.08,14.33.
[0266] 11 B NMR(128 MHz,CDCl 3 ):δ30.60. 28
[0268] 1 H NMR(500 MHz,CDCl 3<h2 style=";text-align:left;direction:ltr">):δ8.00(d,J=8.7 Hz,1H),7.92(d,J=8.3 Hz,1H),7.80(dd,J=6.2,8.4 Hz,2H),7.55(d,J=16.0 Hz,1H),7.48–7.44(m,1H),7.40–7.36(m,1H),7.23–7.18(m,6H),7.16–7.11(m,1H),7.01(d,J=7.9 Hz,2H),5.86(d,J=15.9 Hz,1H),5.25(d,J=12.3 Hz,1H),5.16(d,J=12.3 Hz,1H),2.64–2.48(m,2H),1.55–1.49(m,2H),1.49–1.42(m,2H),0.98(t,J=7.2 Hz,3H),0.70(s,6H),0.61(s,6H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0269] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ167.55,145.88,142.40,137.85,137.56,134.97,133.60,133.36,132.90,129.04,128.4 2,128.40,128.23,128.12,127.47,127.41,127.21,126.97,126.79,126.31,126.18,14.25.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0270] <h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> B NMR(128 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ32.16.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 29<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0272] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3):δ8.03(d,J=8.6 Hz,1H),7.95(d,J=8.5 Hz,1H),7.84(t,J=8.1 Hz,2H),7.60(d,J=16.0 Hz,1H),7.52–7.47(m,1H),7.45–7.39(m,1H),7.24(d,J=4.4 Hz,4H),7.20–7.12(m,1H),6.87(d,J=1.4 Hz,1H),6.83(dd,J=1.5,7.9 Hz,1H),6.67(d,J=7.9 Hz,1H),5.91–5.87(m,3H),5.22(d,J=12.2 Hz,1H),5.14(d,J=12.2Hz,1H),2.70–2.51(m,2H),1.60–1.54(m,2H),1.53–1.47(m,2H),1.03(t,J=7.2 Hz,3H),0.73(s,6H),0.64(s,6H).
[0273] 13 C NMR(126 MHz,CDCl 3 ):δ167.52,147.66,147.35,145.76,142.37,137.79,134.98,133.57,132.93,130.17,128.44,128.21,128.04,127.48,127.27,127.24,127.00,126.74,126.35,126.11,122.15,109.19,108.05,101.06,82.47,66.46,32.61,30.34,24.13,23.05,14.25.
[0274] 11 B NMR(128 MHz,CDCl 3 ):δ29.30. 30
[0276] 1 H NMR(500 MHz,CDCl 3):δ7.98(d,J=8.7 Hz,1H),7.92(d,J=8.3 Hz,1H),7.84–7.77(m,2H),7.61(d,J=16.0 Hz,1H),7.50–7.45(m,1H),7.44(dd,J=0.8,1.5 Hz,1H),7.42–7.36(m,1H),7.27(t,J=1.7 Hz,1H),7.24–7.19(m,4H),7.16–7.11(m,1H),6.36(d,J=1.1 Hz,1H),5.86(d,J=16.0 Hz,1H),5.16(d,J=12.6Hz,1H),5.08(d,J=12.6 Hz,1H),2.69–2.52(m,2H),1.59–1.53(m,2H),1.53–1.44(m,2H),1.01(t,J=7.2 Hz,3H),0.70(s,6H),0.61(s,6H).
[0277] 13 C NMR(126 MHz,CDCl 3 ):δ167.45,145.82,143.08,142.49,141.45,137.84,134.99,133.59,132.92,128.49,128.25,127.97,127.55,127.49,127.31,127.28,127.03,126.76,126.38,126.05,120.86,110.89,82.51,58.11,32.64,30.36,24.17,24.16,23.06,14.30.
[0278] 11 B NMR(128 MHz,CDCl 3 ):δ31.31. 31
[0280] 1 H NMR(500 MHz,CDCl 3<h2 style=";text-align:left;direction:ltr">):δ8.00(d,J=8.6 Hz,1H),7.93(d,J=8.5 Hz,1H),7.81(t,J=8.8 Hz,2H),7.59(d,J=16.0 Hz,1H),7.50–7.44(m,1H),7.43–7.35(m,1H),7.26–7.17(m,5H),7.17–7.10(m,2H),7.02(dd,J=1.1,5.0 Hz,1H),5.87(d,J=16.0 Hz,1H),5.29(d,J=12.6 Hz,1H),5.22(d,J=12.6 Hz,1H),2.74–2.48(m,2H),1.59–1.50(m,2H),1.50–1.42(m,2H),0.99(t,J=7.2 Hz,3H),0.70(s,6H),0.61(s,6H).<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0281] <h2 style=";text-align:left;direction:ltr"> 13 <h2 style=";text-align:left;direction:ltr"> C NMR (126 MHz, CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ167.43,145.81,142.48,137.81,137.27,135.00,133.59,132.91,128.49,128.25,127.99,127.77,127.56,127.49,1 27.37,127.28,127.03,126.79,126.38,126.12,125.76,123.81,82.51,61.79,32.62,30.35,24.19,24.15,23.05,14.29.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0282] <h2 style=";text-align:left;direction:ltr"> 11 <h2 style=";text-align:left;direction:ltr"> B NMR(128 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3 <h2 style=";text-align:left;direction:ltr"> ):δ31.48.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 32<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0284] <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> H NMR(500 MHz,CDCl<h2 style=";text-align:left;direction:ltr"> 3):δ7.90(d,J=8.4 Hz,1H),7.77(d,J=7.7 Hz,1H),7.73(d,J=8.4 Hz,1H),7.67(d,J=15.9 Hz,1H),7.45–7.33(m,7H),7.27–7.23(m,3H),7.17–7.13(m,5H),7.12–7.08(m,1H),7.03–7.00(m,2H),5.74(d,J=15.9 Hz,1H),2.84(ddd,J=6.2,9.0,13.1 Hz,1H),2.69(ddd,J=6.2,9.1,13.1 Hz,1H),1.77–1.61(m,2H),1.59–1.50(m,2H),1.02(t,J=7.3Hz,3H),0.77(s,6H),0.54(s,6H).
[0285] 13 C NMR(126MHz,CDCl 3 ):δ148.21,147.93,147.16,147.09,140.35,140.24,138.66,138.55,137.66,134.90,134.12,133.95,133.90,133.87,133.66,133.59,133.29,133.14,131.09,128.28,128.25,128.22,128.06,127.88,127.84,127.65,127.63,127.50,127.44,127.30,127.28,126.84,126.76,126.43,126.00,82.50,32.90,30.57,24.43,23.85,23.06,14.36.(Due to C-P coupling and the complexity of the spectrum,doublets in the aromatic region cannot be assigned and they are listed assinglets).
[0286] 31 P NMR(202MHz,CDCl 3 ):δ-15.15.
[0287] 11 B NMR(160MHz,CDCl 3 ):δ28.09. 33
[0289] 1 H NMR (400 MHz, CDCl 3 ): δ7.33–7.15(m,10H),6.48(d,J=15.7Hz,1H),6.33(dd,J=15.7,8.5Hz,1H),4 .27(dd,J=10.9,8.5Hz,1H),3.96(d,J=10.9Hz,1H),3.69(s,3H),3.51(s,3H).
[0290] 13 C NMR (101 MHz, CDCl 3 ): δ168.31,167.89,140.27,136.92,131.94,129.21,128.83,128.58,127.97,127.68,127.28,126.49,57.75,52.73,52.55,49.30.
[0291] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.
Claims
1. A method for preparing an axially chiral alkenyl borate containing phosphine or carboxylate, characterized in that: The following steps are involved: (1) Add aromatic 1,3-eneyne, phosphine- or carboxylate-containing aromatic bromide, copper salt, palladium, and ligand into a pressure-resistant sealed reaction vessel, add diboron reagent and base in a glove box, evacuate air, fill with argon, add organic solvent, and stir at 15-40°C for 72-96 hours; (2) The material obtained in step (1) was taken out from the pressure-resistant sealed reaction vessel, cooled to room temperature, and ethyl acetate was added to elute through a silica gel short column to obtain a crude product, which was then washed with 60% ethanol. o The organic phase was extracted three times with water from C; (3) The organic solvent in the organic phase obtained in step (2) is dried by spin drying, purified by using a silica gel column, and then eluted with an eluent to obtain the axially chiral alkenyl borate containing phosphine or carboxylate.
2. The method according to claim 1, characterized in that The aromatic 1,3-enyne is an alkyl-substituted aromatic 1,3-enyne, an aromatic 1,3-enyne with no benzene ring substitution, an aromatic 1,3-enyne with a substituted benzene ring, or an aromatic 1,3-enyne with multiple benzene ring substitutions.
3. The method according to claim 1, characterized in that: The phosphine-containing aryl bromide is a phosphorus-containing aryl bromide with no substitution on the benzene ring of the phosphine, a phosphorus-containing aryl bromide with a single substitution on the benzene ring of the phosphine, or a phosphorus-containing aryl bromide with multiple substitutions on the benzene ring of the phosphine.
4. The method according to claim 1, characterized in that: The carboxylate-containing aryl bromide includes an aryl bromide containing carboxylate without substitution on the benzene ring, an aryl bromide containing carboxylate with mono-substitution on the benzene ring, and an aryl bromide containing carboxylate without substitution on the naphthalene ring.
5. The method according to claim 1, characterized in that The copper salt is one of 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene copper salt and 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene copper salt.
6. The method according to claim 1, characterized in that The palladium catalyst is one of palladium acetate and palladium bromide.
7. The method according to claim 1, characterized in that The ligand is one of (R)-4-(anthracen-9-yl)-3-(tert-butyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole, (S)-3-(tert-butyl)-4-(2,6-dimethoxy-3,5-dimethylphenyl)-2,3-dihydrobenzo[d][1,3]oxaphosphole, and (3aS,8aR)-2-(m-methyl)-3a,8a-dihydro-8H-indeno[1,2-d]dioxazole.
8. The method according to claim 1, characterized in that The diboron reagent is pinacol diborate.
9. The method according to claim 1, characterized in that: The base is one of sodium tert-amylate and sodium tert-butyrate; the organic solvent is one of mesitylene and trifluorotoluene.
10. The method according to claim 1, characterized in that The eluent is a mixed solution of petroleum ether and ethyl acetate; the volume ratio of petroleum ether to ethyl acetate in the eluent is 10:1-3:1.
Citation Information
Patent Citations
Axially chiral phosphine-alkene ligand, and preparation method and application thereof
CN111718372A
Preparation method for and application of chiral spirocyclic phosphine-nitrogen-phosphine tridentate ligand and iridium catalyst thereof
US20230151035A1
Preparation method for and application of 3-substituted chiral spiro aminophosphine ligand on pyridine ring
WO2021083018A1
